Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology

Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology

BackgroundAndrogen deprivation therapy (ADT) is the foundational treatment for metastatic prostate cancer (PCa). Androgen receptor (AR) axis-targeted therapies are a new standard of care for advanced PCa. Although these agents have significantly improved patient survival, the suppression of testoste...

Full description

Bibliographic Details
Main Authors: Darren M. C. Poon, Guang-Ming Tan, Kuen Chan, Marco T. Y. Chan, Tim-Wai Chan, Raymond W. M. Kan, Martin H. C. Lam, Clarence L. H. Leung, Kenneth C. W. Wong, Kevin K. H. Kam, Chi-Fai Ng, Peter K. F. Chiu
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Oncology
Subjects:
abiraterone
apalutamide
darolutamide
degarelix
enzalutamide
gonadotropin-releasing hormone
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1345322/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1345322/full

Similar Items